UROV

Urovant Sciences

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$74.4M

Burn Rate (Qtr)

-$35.2M

Company Profile

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Vibegron (beta-3 adrenergic agonist)

Overactive Bladder (OAB)

PDUFA

December 26, 2020

Vibegron (beta-3 adrenergic agonist)

Over Active Bladder (OAB) in Men with Benign Prostatic Hyperplasia (BPH)

Phase 3 (Top-line Data)

H2 2021

Vibegron (beta-3 adrenergic agonist)

Irritable Bowel Syndrome (IBS) Associated Pain

Phase 2a (Full Data Analysis)

TBA

URO-902

Overactive Bladder (OAB)

Phase 2a (DSMB Meeting)

December 2020 / Early 2021

Recent Posts

See what the community is saying - click to see full post

UROV - Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable

UROV - Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term E

UROV - Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding S

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon